Citations

Clear

196 citation(s) found for "Schultz, M".

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
Kumar, Anita J. , Hemmer, Michael, Arora, Mukta , Pidala, Joseph A. , Couriel, Daniel R. , Aljurf, Mahmoud , Cahn, Jean‐Yves, Cairo, Mitchell S. , Farhan, Shatha , Hale, Gregory A., Hashmi, Shahrukh K. , Inamoto, Yoshihiro , Kamble, Rammurti T., Kharfan‐Dabaja, Mohamed A. , MacMillan, Margaret L. , Marks, David I. , Norkin, Maxim , Ringdén, Olle , Schouten, Harry C. , Solh, Melhem , Urbano-Ispizúa, Álvaro , Verdonck, Leo F. , Hamilton, Betty K. , Majhail, Navneet S. , Loren, Alison W. , Ringden, Olov , Majhail, Navneet S , Kim, Soyoung , Spellman, Stephen R. , Alousi, Amin Majid , Cahn, Jean‐Yves , Cutler, Corey S. , Gergis, Usama , Nakasone, Hideki , Qayed, Muna , Schultz, Kirk R. , Teshima, Takanori , Gale, Robert Peter

Mayo Clinic

Blood Advances | May 8, 2018 | Volume: 2 | Issue: 9 | Pages: 1022-1031

10.1182/bloodadvances.2017013052 | PMID 29739773 Get It

Key Points Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.
Expression of Adipocyte/Macrophage Fatty Acid–Binding Protein in Tumor-Associated Macrophages Promotes Breast Cancer Progression
Hao, Jiaqing , Yan, Fei , Zhang, Yuwen , Triplett, Ashley, Zhang, Ying , Schultz, Debra A., Sun, Yanwen , Zeng, Jun , Silverstein, Kevin A.T. , Zheng, Qi , Bernlohr, David , Cleary, Margot P. , Sauter, Edward R. , Liu, Shujun , Suttles, Jill, Li, Bing , Egilmez, Nejat K.

Mayo Clinic

Cancer Research | February 6, 2018 | Volume: 78 | Issue: 9 | Pages: 2343-2355

10.1158/0008-5472.can-17-2465 | PMID 29437708 Get It

Abstract Tumor-associated macrophages (TAM) play a critical role in cancer development and progression. However, the heterogeneity of TAM presents a major challenge to identify clinically relevant markers for protumor TAM. Here, we report that expression of adipocyte/macrophage fatty acid–binding protein (A-FABP) in TAM promotes breast cancer progression. Although upregulation of A-FABP was inversely associated with breast cancer survival, deficiency of A-FABP significantly reduced mammary tumor growth and metastasis. Furthermore, the protumor effect of A-FABP was mediated by TAM, in particular, in a subset of TAM with a CD11b+F4/80+MHCII−Ly6C− phenotype. A-FABP expression in TAM facilitated protumor IL6/STAT3 signaling through regulation of the NFκB/miR-29b pathway. Collectively, our results suggest A-FABP as a new functional marker for protumor TAM. Significance: These findings identify A-FABP as a functional marker for protumor macrophages, thus offering a new target for tumor immunotherapy. Cancer Res; 78(9); 2343–55. ©2018 AACR.
[O1–02–05]: GENOTYPIC VARIANCE MAY EXPLAIN THE BALANCE OF EARLY CORTICAL VERSUS STRIATAL AMYLOID DEPOSITION IN AUTOSOMAL DOMINANT AD
Graff‐Radford, Neill R., Salloway, Stephen , Buckles, Virginia, Johnson, Keith, Chhatwal, Jasmeer P. , Hanseeuw, Bernard , McDade, Eric , Schultz, Aaron P. , Martins, Ralph N. , Schofield, Peter R. , Masters, Colin L. , Graff‐Radford, Neill R. , Danek, Adrian , Xiong, Chengjie , Goate, Alison , Benzinger, Tammie L.S. , Morris, John C. , Bateman, Randall J. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2017.07.043 Get It

Development of quality metrics for ambulatory pediatric cardiology: Infection prevention
Johnson, Jonathan N. , Barrett, Cindy, Franklin, Wayne H., Graham, Eric M. , Halnon, Nancy , Hattendorf, Brandy, Krawczeski, Catherine D. , McGovern, James J., Vinocur, Jeffrey M. , Chowdhury, Devyani , Anderson, Jeffrey , O’Connor, Matthew J. , Schultz, Amy , Vinocur, Jeffrey M

Mayo Clinic

Congenital Heart Disease | July 25, 2017 | Volume: 12 | Issue: 6 | Pages: 756-761

10.1111/chd.12519 | PMID 28741863 Get It

Acute Cystitis: A Prospective Study of Laboratory Tests and Duration of Therapy
Schultz, Henry J., McCaffrey, Laura, Keys, Thomas F. , Nobrega, Fred T.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 133 | Issue: 2 | Pages: 345-345

10.1016/s0022-5347(17)48938-5 Get It

A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Jack, Clifford R., Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Sadowski, Martin, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Hsiung, Robin, Schultz, Susan, Burns, Jeffrey, Jicha, Gregory, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R. , Hsiung, Ging‐Yuek Robin , Jicha, Gregory A. , Sadowski, Martin , van Dyck, Christopher H, Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Schultz, Susan, Burns, Jeffrey, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1768-1775

10.1212/wnl.0000000000003904 | PMID 28381506 Get It

RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas
Vogelbaum, Michael A. , Brown, Paul D. , Blumenthal, Deborah T. , Biggs, Christopher , Schultz, Carolyn J. , Berkey, Brian A. , Peereboom, David M. , Giannini, Caterina , Suh, John H. , Schultz, C., Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 1520-1520

10.1200/jco.2005.23.16_suppl.1520 Get It

RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma.
Aldape, Ken, Wang, M., Colman, Howard , Jones, G. T., Chakravarti, Arnab , Long, Lihong, Diefes, Kristin, Heathcock, Lindsey, Jenkins, Rosalind E. , Gilbert, M. R., Group, Radiation Therapy Oncology, Sulman, Erik P. , Hegi, Monika E. , Colman, Howard , Mehta, Minesh P. , Andrews, David William , Jenkins, R., Schultz, Carl Johann , Group, Radiation Therapy Oncology

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 29 | Issue: 18_suppl | Pages: LBA2000-LBA2000

10.1200/jco.2011.29.18_suppl.lba2000 Get It

LBA2000 Background: Formalin-fixed, paraffin embedded GBM tumor tissue, adequate for conventional MGMT methylation analyses, was required for entry onto the RTOG 0525 clinical trial. Methods: Four prognostic biomarkers were evaluated on a training set of 220 retrospectively obtained GBM samples, consisting of IDH1 mutation, the glioma-CpG island methylator phenotype (G-CIMP), a microarray-based mRNA panel and a novel MGMT promoter methylation assay. For each biomarker, 2 (IDH1 and mRNA) or 3 subgroups (G-CIMP and MGMT) were defined based on associations with overall survival. All combinations (36 possible) of each of the 4 biomarker-derived subgroups were then defined and compared with survival data and then consolidated into 4 risk groups. Once created in the training set, this model was applied to the RTOG 0525 samples (n=763) for external validation. Results: Application of the molecular risk classification to RTOG 0525 samples (left table) showed a highly significant survival association (p<0.001). When compared to the recursive partitioning analysis (RPA, table on right), this composite molecular classifier better identified patients with long term survival and appears to improve resolution by revealing an additional distinct risk group. The molecular classifier was prognostic in each of the treatment arms individually. Conclusions: Four distinct biomarkers or biomarker panels were tested in GBM. These biomarkers were compared with clinical outcome in a training set to optimize a method to combine them into a classifier. This classifier was then validated on a large sample set from a large phase III clinical trial. This composite panel may represent an improvement over the existing RPA with respect to risk stratification of patients for GBM. Additionally, it has the potential to impact future clinical trial designs and provide enhanced opportunities for personalization of therapy for GBM. Support: NCI U10 CA2121661, U10 CA37422, P50 CA127001. [Table: see text]